A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo

Vaccine

Volumn 27, Issue 50, 2009, Pages 7116-7124

  Thacker, Erin E ^a   Nakayama, Masaharu ^a   Smith, Bruce F ^g   Bird, R Curtis ^g   Muminova, Zhanat ^e   Strong, Theresa V ^c,d,e   Timares, Laura ^c,f   Korokhov, Nikolay ^h   O'Neill, Ann Marie ^g   de Gruijl, Tanja D ⁱ   Glasgow, Joel N ^a,b,d   Tani, Kenzaburo ^j   Curiel, David T ^a,c,d  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g AUBURN UNIVERSITY   (United States)

^h VectorLogics Inc   (United States)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j KYUSHU UNIVERSITY   (Japan)

more..

Author keywords

Adenovirus; Cancer immunotherapy; Dendritic cell; Dog; Vaccine

Indexed keywords

AD5CEA.FF/HCD40L; ADENOVIRUS VECTOR; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; DENDRITIC CELL VACCINE; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; DOG; DRUG SYNTHESIS; GENE TRANSFER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC ORGANISM; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD40; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CD40 LIGAND; CELL LINE; CELL PROLIFERATION; DENDRITIC CELLS; DOGS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; RECOMBINANT PROTEINS; TRANSDUCTION, GENETIC;

EID: 70350568201     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.055     Document Type: Article

References (63)

1. Chen L. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol Today 19 1 (1998) 27-30
2. Geijtenbeek T.B., van Vliet S.J., Engering A., t Hart B.A., and van Kooyk Y. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 22 (2004) 33-54
3. O'Hagan D.T., and Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2 9 (2003) 727-735
4. Mosca P.J., Lyerly H.K., Clay T.M., Morse M.A., and Lyerly H.K. Dendritic cell vaccines. Front Biosci 12 (2007) 4050-4060
5. Cerundolo V., Hermans I.F., and Salio M. Dendritic cells: a journey from laboratory to clinic. Nat Immunol 5 1 (2004) 7-10
6. den Brok M.H., Nierkens S., Figdor C.G., Ruers T.J., and Adema G.J. Dendritic cells: tools and targets for antitumor vaccination. Expert Rev Vaccines 4 5 (2005) 699-710
7. Tuyaerts S., Aerts J.L., Corthals J., Neyns B., Heirman C., Breckpot K., et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 56 10 (2007) 1513-1537
8. Lesterhuis W.J., Aarntzen E.H., De Vries I.J., Schuurhuis D.H., Figdor C.G., Adema G.J., et al. Dendritic cell vaccines in melanoma: from promise to proof?. Crit Rev Oncol Hematol 66 2 (2008) 118-134
9. Proudfoot O., Apostolopoulos V., and Pietersz G.A. Receptor-mediated delivery of antigens to dendritic cells: anticancer applications. Mol Pharm 4 1 (2007) 58-72
10. Arthur J.F., Butterfield L.H., Roth M.D., Bui L.A., Kiertscher S.M., Lau R., et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4 1 (1997) 17-25
11. Lotem M., Zhao Y., Riley J., Hwu P., Morgan R.A., Rosenberg S.A., et al. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. J Immunother 29 6 (2006) 616-627
12. van Leeuwen E.B., Cloosen S., Senden-Gijsbers B.L., Germeraad W.T., and Bos G.M. Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC. Cytotherapy 8 1 (2006) 36-46
13. Zhong L., Granelli-Piperno A., Choi Y., and Steinman R.M. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 29 3 (1999) 964-972
14. Zhang L., Tang Y., Akbulut H., Zelterman D., Linton P.J., and Deisseroth A.B. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci USA 100 25 (2003) 15101-15106
15. Cho H.I., Kim H.J., Oh S.T., and Kim T.G. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine 22 2 (2003) 224-236
16. Noureddini S.C., and Curiel D.T. Genetic targeting strategies for adenovirus. Mol Pharm 2 5 (2005) 341-347
17. Tillman B.W., de Gruijl T.D., Luykx-de Bakker S.A., Scheper R.J., Pinedo H.M., Curiel T.J., et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol 162 11 (1999) 6378-6383
18. Pereboev A.V., Nagle J.M., Shakhmatov M.A., Triozzi P.L., Matthews Q.L., Kawakami Y., et al. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther 9 5 (2004) 712-720
19. Izumi M., Kawakami Y., Glasgow J.N., Belousova N., Everts M., Kim-Park S., et al. In vivo analysis of a genetically modified adenoviral vector targeted to human CD40 using a novel transient transgenic model. J Gene Med 7 12 (2005) 1517-1525
20. Korokhov N., Noureddini S.C., Curiel D.T., Santegoets S.J., Scheper R.J., and de Gruijl T.D. A single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system. Mol Pharm 2 3 (2005) 218-223
21. Belousova N., Korokhov N., Krendelshchikova V., Simonenko V., Mikheeva G., Triozzi P.L., et al. Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol 77 21 (2003) 11367-11377
22. Clement A., Pereboev A., Curiel D.T., Dong S.S., Hutchings A., and Thomas J.M. Converting nonhuman primate dendritic cells into potent antigen-specific cellular immunosuppressants by genetic modification. Immunol Res 26 1-3 (2002) 297-302
23. de Gruijl T.D., Luykx-de Bakker S.A., Tillman B.W., van den Eertwegh A.J., Buter J., Lougheed S.M., et al. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol 169 9 (2002) 5322-5331
24. Pereboev A.V., Asiedu C.K., Kawakami Y., Dong S.S., Blackwell J.L., Kashentseva E.A., et al. Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Ther 9 17 (2002) 1189-1193
25. Huang D., Pereboev A.V., Korokhov N., He R., Larocque L., Gravel C., et al. Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells. Gene Ther 15 4 (2008) 298-308
26. Paoloni M., and Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8 2 (2008) 147-156
27. Khanna C., Lindblad-Toh K., Vail D., London C., Bergman P., Barber L., et al. The dog as a cancer model. Nat Biotechnol 24 9 (2006) 1065-1066
28. Porrello A., Cardelli P., and Spugnini E.P. Oncology of companion animals as a model for humans. An overview of tumor histotypes. J Exp Clin Cancer Res 25 1 (2006) 97-105
29. Waters D.J., and Wildasin K. Cancer clues from pet dogs. Sci Am 295 6 (2006) 94-101
30. Smith B.F., Baker H.J., Curiel D.T., Jiang W., and Conry R.M. Humoral and cellular immune responses of dogs immunized with a nucleic acid vaccine encoding human carcinoembryonic antigen. Gene Ther 5 7 (1998) 865-868
31. Casal M., and Haskins M. Large animal models and gene therapy. Eur J Hum Genet 14 3 (2006) 266-272
32. Seki T., Dmitriev I., Kashentseva E., Takayama K., Rots M., Suzuki K., et al. Artificial extension of the adenovirus fiber shaft inhibits infectivity in coxsackievirus and adenovirus receptor-positive cell lines. J Virol 76 3 (2002) 1100-1108
33. Krasnykh V., Belousova N., Korokhov N., Mikheeva G., and Curiel D.T. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 75 9 (2001) 4176-4183
34. Graham F.L., and Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 3 3 (1995) 207-220
35. Oster W., Lindemann A., Mertelsmann R., and Herrmann F. Regulation of gene expression of M-, G-, GM-, and multi-CSF in normal and malignant hematopoietic cells. Blood Cells 14 2-3 (1988) 443-462
36. Lu L., Srour E.F., Warren D.J., Walker D., Graham C.D., Walker E.B., et al. Enhancement of release of granulocyte- and granulocyte-macrophage colony-stimulating factors from phytohemagglutinin-stimulated sorted subsets of human T lymphocytes by recombinant human tumor necrosis factor-alpha. Synergism with recombinant human IFN-gamma. J Immunol 141 1 (1988) 201-207
37. Krasnykh V.N., Mikheeva G.V., Douglas J.T., and Curiel D.T. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 70 10 (1996) 6839-6846
38. Perreau M., Mennechet F., Serratrice N., Glasgow J.N., Curiel D.T., Wodrich H., et al. Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol 81 7 (2007) 3272-3284
39. Korokhov N., Mikheeva G., Krendelshchikov A., Belousova N., Simonenko V., Krendelshchikova V., et al. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol 77 24 (2003) 12931-12940
40. Bajorath J., Chalupny N.J., Marken J.S., Siadak A.W., Skonier J., Gordon M., et al. Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction. Biochemistry 34 6 (1995) 1833-1844
41. Bajorath J. Detailed comparison of two molecular models of the human CD40 ligand with an X-ray structure and critical assessment of model-based mutagenesis and residue mapping studies. J Biol Chem 273 38 (1998) 24603-24609
42. Weber L.W., Bowne W.B., Wolchok J.D., Srinivasan R., Qin J., Moroi Y., et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 102 6 (1998) 1258-1264
43. Gold J.S., Ferrone C.R., Guevara-Patino J.A., Hawkins W.G., Dyall R., Engelhorn M.E., et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 170 10 (2003) 5188-5194
44. Naftzger C., Takechi Y., Kohda H., Hara I., Vijayasaradhi S., and Houghton A.N. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 93 25 (1996) 14809-14814
45. Hawkins W.G., Gold J.S., Dyall R., Wolchok J.D., Hoos A., Bowne W.B., et al. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 128 2 (2000) 273-280
46. Mahnke K., Qian Y., Fondel S., Brueck J., Becker C., and Enk A.H. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 65 15 (2005) 7007-7012
47. Hauser H., Shen L., Gu Q.L., Krueger S., and Chen S.Y. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther 11 11 (2004) 924-932
48. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S., Soares H., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199 6 (2004) 815-824
49. Yang L., Yang H., Rideout K., Cho T., Joo K.I., Ziegler L., et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 26 3 (2008) 326-334
50. Kretz-Rommel A., Qin F., Dakappagari N., Torensma R., Faas S., Wu D., et al. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother 30 7 (2007) 715-726
51. Pereira C.F., Torensma R., Hebeda K., Kretz-Rommel A., Faas S.J., Figdor C.G., et al. In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model. J Immunother 30 7 (2007) 705-714
52. Mossoba M.E., and Medin J.A. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials. Expert Rev Vaccines 5 5 (2006) 717-732
53. Basak S.K., Kiertscher S.M., Harui A., and Roth M.D. Modifying adenoviral vectors for use as gene-based cancer vaccines. Viral Immunol 17 2 (2004) 182-196
54. Molinier-Frenkel V., Lengagne R., Gaden F., Hong S.S., Choppin J., Gahery-Segard H., et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 76 1 (2002) 127-135
55. Banchereau J. The long arm of the immune system. Sci Am 287 5 (2002) 52-59
56. Finkelman F.D., Lees A., Birnbaum R., Gause W.C., and Morris S.C. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol 157 4 (1996) 1406-1414
57. Mackey M.F., Gunn J.R., Maliszewsky C., Kikutani H., Noelle R.J., and Barth Jr. R.J. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 161 5 (1998) 2094-2098
58. Day M.J., and Immunoglobulin. G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. Vet Parasitol 147 1-2 (2007) 2-8
59. Carvalho L.H., Sano G., Hafalla J.C., Morrot A., Curotto de Lafaille M.A., and Zavala F. IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages. Nat Med 8 2 (2002) 166-170
60. Boag P.R., Parsons J.C., Presidente P.J., Spithill T.W., and Sexton J.L. Characterisation of humoral immune responses in dogs vaccinated with irradiated Ancylostoma caninum. Vet Immunol Immunopathol 92 1-2 (2003) 87-94
61. Fujiwara R.T., Loukas A., Mendez S., Williamson A.L., Bueno L.L., Wang Y., et al. Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs. Vaccine 24 4 (2006) 501-509
62. Breathnach R.M., Fanning S., Mulcahy G., Bassett H.F., Jones B.R., and Daly P. Evaluation of Th1-like, Th2-like and immunomodulatory cytokine mRNA expression in the skin of dogs with immunomodulatory-responsive lymphocytic-plasmacytic pododermatitis. Vet Dermatol 17 5 (2006) 313-321
63. Horiuchi Y., Hanazawa A., Nakajima Y., Nariai Y., Asanuma H., Kuwabara M., et al. T-helper (Th)1/Th2 imbalance in the peripheral blood of dogs with malignant tumor. Microbiol Immunol 51 11 (2007) 1135-1138